Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Sponsor: Alkermes, Inc.
Summary
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
176
Start Date
2026-04
Completion Date
2027-06
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
ALKS 2680 Dose 1
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 2
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 3
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Placebo
Participants will receive placebo tablets, daily, orally for 12 weeks